What's new

Human medicines European public assessment report (EPAR): Daptomycin Hospira, daptomycin, Date of authorisation: 22/03/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Daptomycin Hospira, daptomycin, Date of authorisation: 22/03/2017, Revision: 14, Status: Authorised

Feb 17, 2025 - 17:21
 0
Human medicines European public assessment report (EPAR): Daptomycin Hospira, daptomycin, Date of authorisation: 22/03/2017, Revision: 14, Status: Authorised
Human medicines European public assessment report (EPAR): Daptomycin Hospira, daptomycin, Date of authorisation: 22/03/2017, Revision: 14, Status: Authorised
Read More

Tags:

Previous Article

EMEA-002713-PIP02-21-M01

Next Article

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Va...

Related Posts

Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025  0

Summary of opinion: Imfinzi, 27/02/2025 Positive

Summary of opinion: Imfinzi, 27/02/2025 Positive

Feb 28, 2025  0

SPOR and xEVMPD Stakeholder Engagement Webinars : Product Management Service (XEVMPD) for MAH, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 10 October 2024, 10:00 (CEST) to 10 October 2024, 12:00 (CEST)

SPOR and xEVMPD Stakeholder Engagement Webinars : Produ...

Apr 1, 2025  0